Abstract Number: 1908 • 2012 ACR/ARHP Annual Meeting
Multinational Evidence-Based Recommendations for Diagnosis and Management of Gout: Integrating Systematic Literature Research and Expert Opinion of a Broad Panel of Rheumatologists in the 3E Initiative
Background/Purpose: The 3e (Evidence, Expertise, Exchange) Initiative is a multinational collaboration that aims to promote evidence-based medicine in rheumatology. The 2011-12 3e Initiative aimed to…Abstract Number: 1910 • 2012 ACR/ARHP Annual Meeting
Regulation of Microrna 223 Expression in a Gouty Arthritis
Background/Purpose: Gout is an inflammatory chronic disease caused by deposition of uric acid crystals in the joint and connective tissues causing pain and disability. Current…Abstract Number: 1911 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT
Background/Purpose: The primary treatment goals for gouty arthritis (GA) are rapid relief of pain and inflammation during acute attacks, and long-term hyperuricemia management. A post-hoc…Abstract Number: 1912 • 2012 ACR/ARHP Annual Meeting
Colchicine, As Assessed by Target Joint Pain Scores, Is Effective At 16 Hours in Patients with Acute Gout Flares
Background/Purpose: The management of patients with gout remains suboptimal, leading to increasing frequency and severity of recurrent flares that eventually lead to joint destruction and…Abstract Number: 1913 • 2012 ACR/ARHP Annual Meeting
Complete Tophus Response in Patients with Chronic Gout Initiating Pegloticase Treatment
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase that acts via enzymatic degradation of uric acid to allantoin, is approved in the US for the treatment…Abstract Number: 1914 • 2012 ACR/ARHP Annual Meeting
The Diagnosis and Management of Gout in 2012: Survey of US and Canadian Rheumatologists
Background/Purpose: The introduction of novel treatment modalities for gout has escalated interest and education on this topic. Although gout is the most common inflammatory arthropathy…Abstract Number: 1915 • 2012 ACR/ARHP Annual Meeting
Elevated Serum Homocysteine Levels Were Related Not with Serum Uric Acid Levels but with Decreased Renal Function in Chronic Gouty Patients
Background/Purpose: Hyperhomocysteinemia, which is related with cardiovascular diseases and metabolic syndrome, is regarded as one of the important factors in endothelial cell damage processes. It…Abstract Number: 1916 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid As a Biomarker for Mitigation of Infusion Reactions in Patients Treated with Pegloticase for Refractory Chronic Gout
Background/Purpose: Using data pooled from the randomized, placebo-controlled trials (RCTs) of pegloticase, post-hoc analyses of urate-lowering, antibody titers and the patterns of infusion-related reactions (IRs)…Abstract Number: 1812 • 2012 ACR/ARHP Annual Meeting
A Retrospective Evaluation of the Clinical and Economic Implications of Gout in Nursing Home Residents in Hawaii Treated with Allopurinol
Background/Purpose: We describe patient characteristics, serum uric acid (sUA) levels while on allopurinol, and activities of daily living (ADL) in nursing home residents with gout.…Abstract Number: 1813 • 2012 ACR/ARHP Annual Meeting
Accuracy of Veterans Affairs Database for Gout-Related Health Care Utilization
Background/Purpose: Gout outcome studies have used administrative and claims databases. It is unknown whether administrative-derived data are accurate for gout-related utilization. The goal of the…Abstract Number: 1814 • 2012 ACR/ARHP Annual Meeting
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Background/Purpose: Gout is a common acute and potentially progressive disease affecting approximately 8 million Americans. Hyperuricemia (serum urate levels [sUA] >6.8mg/dL) is a major pathogenic…Abstract Number: 1815 • 2012 ACR/ARHP Annual Meeting
Factors Associated with a Prolonged Hospital Length of Stay for Patients with Acute Gout
Background/Purpose: Management of gout in the hospital setting has been poor. This study aimed to describe patient characteristics and the treatment patterns of acute gout…Abstract Number: 1816 • 2012 ACR/ARHP Annual Meeting
Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout
Background/Purpose: Gout is a chronic inflammatory disease caused by the deposition of monosodium urate crystals in joints and soft tissues. The overall prevalence is increasing…Abstract Number: 1661 • 2012 ACR/ARHP Annual Meeting
CCR1 Potentiates Gouty Inflammation Following Initial CXCR2-Dependent Neutrophil Recruitment to Sites of Monosodium Urate Crystal Deposition in Mice
Background/Purpose: During attacks of acute gouty arthritis, monosodium urate (MSU) crystals elicit a potent neutrophilic inflammatory response in the affected joint, causing exquisite pain and…Abstract Number: 1628 • 2012 ACR/ARHP Annual Meeting
Epistatic Interaction Between Solute Carrier 2A9 Genotype and Sugar-Sweetened Beverage Consumption in the Determination of Gout Risk
Background/Purpose: Consumption of drinks sweetened with sugar or high fructose corn syrup increases both serum urate levels and the risk for gout. SLC2A9 encodes a…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »